How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease

被引：0
|
作者：
Fujioka, Hayato [1 ]
Kataoka, Naoya [1 ]
Imamura, Teruhiko [1 ]
机构：
[1] Univ Toyama, Dept Internal Med 2, Toyama, Japan
来源：
INTERNAL MEDICINE | 2024年 / 63卷 / 15期
关键词：
uric acid; SGLT2; inhibitor; cardiovascular disease; heart failure;
D O I：
10.2169/internalmedicine.2725-23
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2227 / 2227
页数：1
相关论文
共 50 条
  • [31] Safety Profile and Effectiveness of Dapagliflozin in Pediatric Patients with Chronic Kidney Disease
    Van Reeth, Olil
    Caliment, Ancuta
    Garcia, Isabel de la Fuente
    Niel, Olivier
    AMERICAN JOURNAL OF NEPHROLOGY, 2024, 55 (04) : 463 - 467
  • [32] Dapagliflozin Improves the Clinical Outcomes of Patients with Chronic Kidney Disease and Albuminuria
    Stephanie A. Patrick
    Tracey D. Dabal
    Christopher D. Jackson
    Journal of General Internal Medicine, 2021, 36 : 2915 - 2917
  • [33] SHORT-TERM EFFICACY OF DAPAGLIFLOZIN FOR CHRONIC KIDNEY DISEASE PATIENTS
    Nakai, Kentaro
    Hara, Yuichiro
    Inoue, Megumi
    Shukuri, Tomoya
    Hara, Masatoshi
    Nakagawa, Kaneyasu
    Tokumoto, Masanori
    JOURNAL OF HYPERTENSION, 2023, 41 : E420 - E420
  • [34] Impact of hyperuricemia and chronic kidney disease on the prevalence and mortality of cardiovascular disease in cancer survivors
    Chen, Yanlin
    Chen, Yuhan
    Lin, Weidong
    Fu, Lu
    Liu, Huiyi
    Pu, Sijia
    Chen, Haowei
    Yi, Hong
    Xue, Yumei
    CANCER MEDICINE, 2024, 13 (09):
  • [35] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Matsuo, Hiroshi
    Ishikawa, Eiji
    Machida, Hirofumi
    Mizutani, Yasuhide
    Tanoue, Akiko
    Ohnishi, Takahiro
    Murata, Tomohiro
    Okamoto, Shinya
    Ogura, Toru
    Nishimura, Yuki
    Ito, Hiroo
    Yasutomi, Masashi
    Katayama, Kan
    Nomura, Shinsuke
    Ito, Masaaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2020, 24 (04) : 307 - 313
  • [36] Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia
    Hiroshi Matsuo
    Eiji Ishikawa
    Hirofumi Machida
    Yasuhide Mizutani
    Akiko Tanoue
    Takahiro Ohnishi
    Tomohiro Murata
    Shinya Okamoto
    Toru Ogura
    Yuki Nishimura
    Hiroo Ito
    Masashi Yasutomi
    Kan Katayama
    Shinsuke Nomura
    Masaaki Ito
    Clinical and Experimental Nephrology, 2020, 24 : 307 - 313
  • [37] The Effectiveness and Safety of Febuxostat for Chronic Kidney Disease Patients with Gout and Hyperuricemia
    Huang, Chien-Huei
    Wang, Ming-Cheng
    Yen, Chi-Tai
    Cheng, Ching-Lan
    Liu, Pheng-Ying Yeh
    Chang, Hui-Jen
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 : 435 - 436
  • [38] Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection
    Jan T. Kielstein
    Roberto Pontremoli
    Michel Burnier
    Current Hypertension Reports, 2020, 22
  • [39] Management of Hyperuricemia in Patients with Chronic Kidney Disease: a Focus on Renal Protection
    Kielstein, Jan T.
    Pontremoli, Roberto
    Burnier, Michel
    CURRENT HYPERTENSION REPORTS, 2020, 22 (12)
  • [40] EFFECTS OF HYPERURICEMIA AND HYPERTENSION ON RENAL ARTERIOLOPATHY IN CHRONIC KIDNEY DISEASE PATIENTS
    Kentaro, Kohagura
    Tsuyoshi, Miyagi
    Masako, Kochi
    Kunitoshi, Iseki
    Yusuke, Ohya
    NEPHROLOGY, 2014, 19 : 165 - 166
12345